Latest updates · 21 October 2026
In the full issue →AI drug design is producing lab-tested results: Anthropic says Claude designed protein binders against scorpion neurotoxins, and Sinopia Biosciences has won a $2.5 million NIH grant for a metabolomics foundation model.
Research, industry & policy
- How Claude designed protein binders against scorpion neurotoxins, Anthropic · 20 Oct 2026: Adaptyv Bio and Twist Bioscience tested 211 designs for binding and 17 met the criteria; all 211 designs and their data are being released.
- Sinopia Biosciences secures $2.5M NIH grant for metabolomics foundation model, BioSpace · 20 Oct 2026: The grant will advance a metabolomics foundation model for drug discovery.
Why it matters
Open release of both hits and misses gives the field rare, testable data on how well AI designs work in the lab.
